BDA Advises Founder on Sale of Diagnostic Biotech Company CHROMagar SAS
Summary
The buyer has existing activities and knowledge in the field of chromogenic media, a strategic plan to expand its biotech business, and the capabilities to support CHROMagar’s continued growth.BDA is headquartered in New York with offices in London, Dubai, Mumbai, Ho Chi Minh City, Hong Kong, Shanghai, Beijing, Seoul, and Tokyo.The buyer has existing activities and knowledge in the field of chromogenic media, a strategic plan to expand its biotech business, and the capabilities to support CHROMagar’s continued growth.Andrew Huntley, Senior Managing Director at BDA, said, “We are delighted to have helped CHROMagar close this successful transaction.Medical technology is a sector where we are experiencing significant appetite for cross-border transactions involving Japanese parties.”BDA Deal TeamAndrew Huntley, Senior Managing Director, LondonJeff Acton, Managing Director, TokyoNoriyuki Sonoda, Chairman – Japan, TokyoStephane Nakhle, Analyst, LondonIf you have questions, please contact Andrew Huntley in London ahuntley@bdapartners.com or Jeff Acton in Tokyo jacton@bdapartners.com.About CHROMagarCHROMagar supplies the widest range of chromogenic culture media available, covering applications in clinical bacteriology, industrial microbiology, and quality control for food and beverage industries, water testing and environmental monitoring.BDA is headquartered in New York with offices in London, Dubai, Mumbai, Ho Chi Minh City, Hong Kong, Shanghai, Beijing, Seoul, and Tokyo.
Classifications
AskAI Classifications
LabelsLinked Companies
